Evaluate suitability of one nanoparticle platform for veterinary vaccines.

November 2019 — March 2021

Two component VLP-like nanoparticles

Pre-F prot

p67N-nanoparticle
component A fusion

C3d/CD40L-nanoparticle
component B fusion

Objectives

1) Assess the efficacy of nanoparticles to deliver the pre-F protein from bovine respiratory syncytial virus (bRSV), compared with soluble protein.

2) Assess antigen dose reduction using nanoparticles as delivery system against bRSV.

PIs: Anna Lacasta

Partners: Musa Mulongo - TAHSSL

Funding: TAHSSL - BMGF

Highlight of 2020 achievements

- Identification of two regions in Kenya with animals negative for bRSV: Machakos (Kapiti Research Station) and Nyeri (Shamba Sacco).

- Generation of good quality pre-F self assembled nanoparticles.